Testing effectiveness (Phase 2)Active Not RecruitingNCT04640623
What this trial is testing
TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Who this might be right for
Urinary Bladder Neoplasms
Janssen Research & Development, LLC 220